Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | STAT3 | P40763 | 11/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | CCR6 | P51684 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22909484 | 0.76 | CA1 (0.40) | LMNASMN1; SMN2ALDH1A1KMT2A | |
| SCHEMBL22909462 | 0.68 | L3MBTL1 (0.46) | SMN1; SMN2ALDH1A1TP53KMT2A | |
| SCHEMBL29729069 | 0.68 | L3MBTL1 (0.46) | SMN1; SMN2ALDH1A1TP53KMT2A | |
| SCHEMBL11201092 | 0.68 | MAPT (0.50) | LMNASMN1; SMN2ALDH1A1TP53MAPT | |
| SCHEMBL3300753 | 0.68 | MAPT (0.50) | LMNASMN1; SMN2ALDH1A1TP53MAPT | |
| SCHEMBL22814180 | 0.68 | ALDH1A1 (0.51) | LMNASMN1; SMN2ALDH1A1TP53MAPT | |
| SCHEMBL29671277 | 0.66 | CA1 (0.35) | — | |
| SCHEMBL22909293 | 0.66 | CA1 (0.35) | — | |
| SCHEMBL3234878 | 0.65 | MAPT (0.47) | LMNASMN1; SMN2ALDH1A1TP53MAPT | |
| SCHEMBL22814199 | 0.65 | RAPGEF4 (0.58) | LMNASMN1; SMN2ALDH1A1TP53MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12559454-B2 | Benzenesulfonamide derivatives and uses thereof | 2692372 ONTARIO, INC. (CA) | 2026-02-24 | — | — | US | disclosed |
| US-20220281812-A1 | BENZENESULFONAMIDE DERIVATIVES AND USES THEREOF | 2692372 ONTARIO INC (CA) | 2022-09-08 | — | — | US | disclosed |
| EP-4017843-A1 | BENZENESULFONAMIDE DERIVATIVES AND USES THEREOF | 2692372 Ontario, Inc. (CA) | 2022-06-29 | — | — | EP | disclosed |
| CN-114502533-A | Benzenesulfonamide derivatives and use thereof | 2692372安大略公司 | 2022-05-13 | — | — | CN | disclosed |
| WO-2021009568-A1 | BENZENESULFONAMIDE DERIVATIVES AND USES THEREOF | 2692372 ONTARIO, INC. (CA) | 2021-01-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12559454-B2 | Benzenesulfonamide derivatives and uses thereof | NR2E1, NR2C2, NR3C1 | LMNA 1384/4885SMN1; SMN2 1102/4885ALDH1A1 4335/4885 |
| US-20220281812-A1 | BENZENESULFONAMIDE DERIVATIVES AND USES THEREOF | BCR, ARSA, VHL | LMNA 616/4885SMN1; SMN2 1225/4885ALDH1A1 2734/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.